Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of TECAR Therapy in Patients With Fibromyalgia

NCT: NCT07769177 · COMPLETED

NCT IDNCT07769177
StatusCOMPLETED
Start Date2025-04-07
Completion2026-06-15
SponsorAnkara City Hospital Bilkent (OTHER)
First posted
Last updated

Brief Summary

A total of 46 patients aged 18-65 years diagnosed with fibromyalgia according to the 2016 ACR criteria, whose most painful region was axial (neck, back, or lower back), were included in the study and randomly assigned upon admission into treatment ($n=23$) and sham control ($n=23$) groups. The treatment group received real TECAR therapy using the BTL-6000 TR Therapy Pro device for a total of 6 sessions over 3 weeks at a frequency of 2 days per week (each 30-minute session consisting of 10 minutes of capacitive and 5 minutes of resistive modes applied to each of the 2 most painful regions), while the control group underwent the exact same protocol applied as sham therapy at 1% power in pulsed mode.

Frequently Asked Questions

What is Efficacy of TECAR Therapy in Patients With Fibromyalgia?

Efficacy of TECAR Therapy in Patients With Fibromyalgia is a clinical trial registered under NCT07769177. Current status: COMPLETED.

What is the status of NCT07769177?

The current status of NCT07769177 (Efficacy of TECAR Therapy in Patients With Fibromyalgia) is: COMPLETED.

When did Efficacy of TECAR Therapy in Patients With Fibromyalgia start?

Efficacy of TECAR Therapy in Patients With Fibromyalgia started on 2025-04-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.